Financial Release TSPC FY 2025.pdf

The aforementioned Tempo Scan's FY 2025 consolidated net sales performance major
benefactors were as follows:

1)

2)

Tempo Scan's Consumer Products & Cosmetics (“CPC”) division was
able to register a healthy net sales growth which increased by 6.7” and
amounted to Rp.4,859.7 billion. This division's biggest net sales benefactor
continued to be its Consumer Products group which net sales had risen by 4.59
and amounted to Rp.3,820.7 billion. In addition, its Cosmetics group's net sales
performance had delivered a strong growth, and its net sales rose by 15.56 and
amounted to Rp.1,039.0 billion.

Commensurately with the aforesaid net sales performance, the CPC division's
Consumer Products group and Cosmetics group net sales contributions toward this
division total net sales were 78.6Yo and 21.4Yo respectively for FY 2025, such a
contribution was slightly changed when compared to these net sales contributions
in previous year which were at 80.3Y6 and 19.7Yo respectively.

For FY 2025, the CPC division's international business net sales was able to
maintained its robust growth and registered a significant net sales increase of
25.9Yo. Such a strong net sales performance was contributed primarily by
its Consumer Products and Cosmetics which aggregate net sales have
increased by 26.10 and 25.8Yo respectively. Conseguently, this CPC
division's International Business net sales contribution towards its total net sales
had increased to become 5.096 compared to its net sales contribution in FY 2024
which was 4.3Y0.

Tempo Scan's Pharmaceutical division has also been able to manage its
net sales growth by 1.4” and amounted to Rp.4,810.9 billion, such a
growth rate was lower when compared to this division net sales growth rate in
previous year due to weaker market demand.

This division net sales growth main contributor continued to be its Consumer
Health products group which net sales increased by 1.3Yo and amounted
to Rp.4,728.0 billion. This Consumer Health group's net sales increase was
contributed by its Consumer Health group's OTC and Vitamins products
net sales which has risen by 4.3”/o. On the other hand, its Nutritional products'
net sales performance was slightly declined by 1.796, in line with the nutritiona!
market negative growth rate in 2025.

Moving on to the Pharmaceutical division Prescription Medicine products' net sales
had registered net sales increased by 7.2Y6 and amounted to Rp.82.9 billion.
Therefore, for FY 2025 Tempo Scan's Consumer Health products group and its
Prescription Medicines group net sales contributions toward its Pharmaceutical
division's total net sales were 98.3Y6 and 1.7Yo respectively.

dm

In addition, the Pharmaceutical division's international business net sales had grew
significantly, and in aggregate such international business had increased by 21.2Y6
and amounted to Rp.320.7 billion. Such net sales result was sharp contrast
compared to its net sales in the previous year which grew negatively by 8.3Y0.
Conseguently, the aforementioned Pharmaceutical international business' net
sales contribution towards Tempo Scan's Pharmaceutical division total net sales
was 6.796 or higher when compared to its net sales contribution of 5.6Yo in
previous year.

3) Tempo Scan's Distribution division net sales declined by 0.496 and amounted to
Rp.4,334.4 billion. Its main contributor of this division net sales growth. was its
Non-Pharma Principals' products which net sales had decreased by 2.7Y6 and
amounted to Rp.3.796,0 billion, while on the other hand this division Pharma
Principals' prescription products registered an increase of 20.1Yo and amounted
to Rp.538.4 billion. Correspondingly, the aforesaid Non-Pharma Principals'
products and Pharma Principals' products net sales contributions toward the
Distribution division total net sales stood at 87.6Yo and 12.4Yo respectively, such
a contribution was marginally changed when compared to these net sales
contributions in previous year which were at 89.7Y6 and 10.3Yo respectively.

In connection with the above, Tempo Scan's CPC division and its Pharmaceutical
division aggregate net sales contribution towards Tempo Scan's consolidated net sales
was 69.1Yb in FY 2025, while in the previous year these 2 divisions' net sales aggregate
contribution was lower and stood at 68.1Yo.

Furthermore, for FY 2025 Tempo Scan's gross profit result registered an
increase of 2.8”o and amounted to Rp.5,324.5 billion, such an increase was
higher compared to its net sales growth rate, hence as a result its gross profit
margin had slightly increased to become 38.0Yo versus its gross profit
margin in the previous year which was 37.9Yo.

The above consolidated gross profit margin result was attributed to Tempo Scan's CPC
division gross profit margin which was eroded from 54.3Y6 in previous year and down
to become 53.46 in FY 2025. On the other hand, Tempo Scan's Pharmaceutical
division gross profit margin had increased to 49.590 versus previous year which gross
profit margin was 49.3Yo. Furthermore, its Distribution division's gross profit margin
had decreased to 8.0Y6 compared to its margin in previous year which was 8.496.

Moving on to Tempo Scan's total operating expenses for FY 2025, it has increased by
7.6Yo and amounted to Rp.3,624.9 billion, such an increase was attributed amongst
others by its total selling expenses that had increased by 8.8Yo and amounted to
Rp.3,030.0 billion, this increase was reguired to maintain Tempo Scan's brand eguities
market share position. Conseguentty, its total selling expenses as a ratio to Tempo
Scan's consolidated net sales was 21.6Y6 or higher compared to previous year whereas
such ratio was still at 20.4Yo.

Moreover, its total general administrative expenses increased by 0.3Yc and amounted
to Rp.697.9 billion, therefore the aforesaid total general administrative expenses ratio
towards Tempo Scan's consolidated net sales was 5.0Y6 or slightly lower when
compared to the same ratio in previous year which was 5.1Y6.

In addition, Tempo Scan's net other operating income amounted to Rp.102.9 billion,
which was a decreased by 7.1Yo compared to previous year which was Rp.110.8
billion. The aforementioned net amount was predominantly derived from its foreign
currencies reserved fund exchange rate gain.

Commensurately with the above result, Tempo Scan's operating profit for FY
2025 decrease by 6.046 and amounted to Rp.1,699.6 billion, correspondingly its
operating profit margin has also decreased to become 12.1Yo which was a relatively
moderate decreased when compared to previous year whereas its operating profit
margin was stood at 13.2Y0.

Furthermore, for FY 2025 its net non-operating income had decreased and amounted
to Rp.122.3 billion or slightly lower compared to previous year which amount was
Rp.126.7 billion.

As the result, Tempo Scan's FY 2025 net profit after tax had decreased moderately by
2.8Yo and amounted to Rp.1,406.8 billion, conseguentty its net profit after tax margin
stood at 10.0Y6 or slightly lower versus its net profit after tax margin in the previous
year which was stood at 10.6Y9.

Commensurately with the above, Tempo Scan's EBITDA had decrease by 9.8Yo and
amounted to Rp.2.031,5 billion, conseguently its EBITDA margin for FY 2025 had also
declined to 14.5Y6 or lower compared to its EBITDA margin in previous year which
was stood at 16.5Y6.

As pertained to Tempo Scan's balance sheet position as of 31 December 2025, it
remained solid whereas its cash and cash eguivalent position total amount stood at
Rp.4,638.0 billion or an increase of 4.1Yo compared to previous year. In addition, its
net operating cycle was at 75 days which was still inline given extremely challenging
market condition. Furthermore, Tempo's Scan total assets and shareholders'
eguity were amounted to Rp.13,085.2 billion and Rp.9,660.1 billion
respectively.

Tempo Scan's Board of Directors would like to express our highest appreciation to all
Tempo Scan's Board Commissioners, its management team and all of its employees
for their continuous support, advise, dedication, commitment and hard works. As well
as to our valued shareholders, business partners, vendors, customers and professional
parties that has made Tempo Scan can achieved the abovementioned financial
results.

W

Jakarta, 30 March 2026
On behalf of PT. Tempo Scan Padific, Tbk.

I Made Dharma Wijaya
President Director

Copies:
- Mr. Handojo S. Muljadi, Tempo Scan's Executive Chairman
- Tempo Scan's Board of Directors